Neurological development of children who are HIV-exposed and uninfected

Dev Med Child Neurol. 2021 Oct;63(10):1161-1170. doi: 10.1111/dmcn.14921. Epub 2021 May 14.

Abstract

Widespread use of antiretroviral drugs for pregnant/breastfeeding females with human immunodeficiency virus (HIV) has led to declining vertical transmission. Despite being HIV-uninfected, the increasing number of children who are HIV-exposed and uninfected (CHEU) often present with developmental alterations. We review seminal and recent evidence on the neurological development of CHEU and associations with early life HIV/antiretroviral exposure. Our conceptual model highlights the numerous exposures and universal risk factors for CHEU developmental disorders. Early studies suggest a significant association between HIV exposure and neurological abnormalities, varying according to the burden of HIV-specific exposures and other risk factors. More recent observations from the modern era are inconsistent, although some studies suggest specific antiretrovirals may adversely affect neurological development of CHEU. As the CHEU population continues to grow, alongside simultaneous increases in types and combinations of antiretrovirals used in pregnancy, long-term monitoring of CHEU is necessary for understanding the effects of HIV/antiretroviral exposure on CHEU developmental outcomes. What this paper adds Evidence on the neurological development of children who are human immunodeficiency virus (HIV)-exposed and uninfected (CHEU) is synthesized. Comparisons are made to children who are HIV-unexposed, across treatment eras and settings, and by antiretroviral drug regimens and drug classes. CHEU exposures are complex and include HIV-specific and universal risk factors which may affect development during the early years of life.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Breast Feeding / statistics & numerical data
  • Child, Preschool
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Integrase Inhibitors / therapeutic use
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical / prevention & control
  • Malnutrition / epidemiology
  • Neurodevelopmental Disorders / epidemiology*
  • Poverty / statistics & numerical data
  • Pregnancy
  • Pregnancy Complications / epidemiology
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / epidemiology
  • Prenatal Exposure Delayed Effects / epidemiology*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Risk Factors

Substances

  • Anti-HIV Agents
  • HIV Integrase Inhibitors
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors